Dr. Lal PathLabs has announced the acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) and plans to establish a wholly owned subsidiary in Dubai, United Arab Emirates.
This strategic move is set to enhance the company's presence in the diagnostics sector both domestically and internationally.
Dr. Lal PathLabs has acquired a 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL) from its existing shareholders.
The acquisition, valued at a cash consideration not exceeding ₹20 crore, will see SDCPL become a wholly owned subsidiary of Dr. Lal PathLabs.
SDCPL, incorporated on July 30, 2021, in Maharashtra, is engaged in providing diagnostic services. The acquisition aims to strengthen Dr. Lal PathLabs' presence in Mumbai and the state of Maharashtra.
SDCPL has reported turnovers of ₹6.11 crore, ₹5.96 crore, and ₹5.42 crore for the financial years 2026, 2025, and 2024, respectively. The acquisition is expected to be completed by May 31, 2026.
In addition to the acquisition, Dr. Lal PathLabs plans to incorporate a wholly owned subsidiary in Dubai, United Arab Emirates, under the name Dr. Lal PathLabs FZCO, subject to necessary regulatory approvals.
This subsidiary will focus on strategic investments in diagnostics and allied activities, including potential acquisitions, tie-ups, or joint ventures.
Read More: Samvardhana Motherson To Acquire Full Control of Nissin India with 51% Stake Buyout from Nissin Electric!
The acquisition of SDCPL and the establishment of a subsidiary in Dubai are part of Dr. Lal PathLabs' strategy to expand its footprint in the diagnostics industry.
By acquiring SDCPL, the company aims to solidify its market position in Maharashtra, while the Dubai expansion provides a gateway to international markets.
As of April 30, 2026, at 3:30 PM, Dr. Lal PathLabs share price on NSE was closed at ₹1,367.20 down by 2.19% from the previous closing price.
Dr. Lal PathLabs' acquisition of Shahbazkers Diagnostic Centre and its expansion into Dubai mark significant steps in the company's growth strategy. These moves are poised to enhance its market presence both in India and abroad, aligning with its vision to become a leading player in the diagnostics sector.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 1, 2026, 11:21 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
